House Democrats proposed forming an entity that would determine the cost effectiveness of drugs and devices being considered for Medicare and Medicaid coverage. This suggestion fails to take into account disease variation and other scientific factors that influence treatment decisions, Dr. Scott Gottlieb writes. He recommends that the government consider guidelines from medical groups in weighing rival technology and that the FDA allow private firms to use findings from their comparative studies to promote products to expert buyers.

Related Summaries